GoHealth(US:GOCO)2025-05-13 11:14Financial Performance - GoHealth's Q1 2025 revenue increased to $221 million, a 19% increase compared to $1856 million in Q1 2024[11] - Adjusted EBITDA for Q1 2025 was $421 million, a 56% increase from $269 million in Q1 2024[11] - Cash flow from operations improved significantly, from -$124 million in Q1 2024 to $125 million in Q1 2025, a 199% increase[14] - Ending commissions receivable (current and non-current) increased by 19%, from $8431 million on March 31, 2024, to $10006 million on March 31, 2025[14] - Adjusted EBITDA margin increased from 145% to 190%[23] Unit Economics - Sales per submission decreased by 15%, from $856 in Q1 2024 to $724 in Q1 2025[16] - Direct operating cost per submission improved by 18%, decreasing from $640 in Q1 2024 to $522 in Q1 2025[16] Non-GAAP Measures - The company uses non-GAAP financial measures like EBITDA, Adjusted EBITDA, and Adjusted EBITDA Margin to evaluate business performance[7] - Adjusted EBITDA is calculated by adjusting EBITDA for items like severance costs, share-based compensation, professional services, operating lease impairment, and legal fees[7, 23]